BioLineRx (BLRX) Competitors $3.63 -0.01 (-0.27%) Closing price 03:58 PM EasternExtended Trading$3.53 -0.10 (-2.75%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLRX vs. RNTX, ATHE, RNXT, ATRA, PRLD, XLO, SCYX, ACRV, BRNS, and AKTXShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Rein Therapeutics (RNTX), Alterity Therapeutics (ATHE), RenovoRx (RNXT), Atara Biotherapeutics (ATRA), Prelude Therapeutics (PRLD), Xilio Therapeutics (XLO), SCYNEXIS (SCYX), Acrivon Therapeutics (ACRV), Barinthus Biotherapeutics (BRNS), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. Rein Therapeutics Alterity Therapeutics RenovoRx Atara Biotherapeutics Prelude Therapeutics Xilio Therapeutics SCYNEXIS Acrivon Therapeutics Barinthus Biotherapeutics Akari Therapeutics Rein Therapeutics (NASDAQ:RNTX) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Is RNTX or BLRX more profitable? Rein Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -90.57%. Rein Therapeutics' return on equity of -74.08% beat BioLineRx's return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -74.08% -27.93% BioLineRx -90.57%-163.37%-34.21% Which has higher valuation & earnings, RNTX or BLRX? Rein Therapeutics has higher earnings, but lower revenue than BioLineRx. Rein Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$15.73M-$2.86-0.67BioLineRx$28.94M0.41-$60.61M-$8.80-0.41 Which has more volatility & risk, RNTX or BLRX? Rein Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Does the MarketBeat Community favor RNTX or BLRX? BioLineRx received 507 more outperform votes than Rein Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRein TherapeuticsN/AN/ABioLineRxOutperform Votes50771.31% Underperform Votes20428.69% Do analysts rate RNTX or BLRX? BioLineRx has a consensus target price of $26.00, suggesting a potential upside of 624.23%. Given BioLineRx's stronger consensus rating and higher possible upside, analysts plainly believe BioLineRx is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioLineRx 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor RNTX or BLRX? In the previous week, Rein Therapeutics had 2 more articles in the media than BioLineRx. MarketBeat recorded 4 mentions for Rein Therapeutics and 2 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.00 beat Rein Therapeutics' score of -0.60 indicating that BioLineRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of RNTX or BLRX? 90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryRein Therapeutics beats BioLineRx on 9 of the 16 factors compared between the two stocks. Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.95M$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.418.9726.6219.77Price / Sales0.41253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book0.496.486.814.53Net Income-$60.61M$143.98M$3.23B$248.18M7 Day Performance16.18%3.37%4.05%1.06%1 Month Performance23.79%7.83%11.64%14.68%1 Year Performance-85.59%-2.24%17.11%6.87% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx1.654 of 5 stars$3.63-0.3%$26.00+616.3%-85.4%$12.08M$28.94M-0.4140News CoverageUpcoming EarningsAnalyst ForecastRNTXRein TherapeuticsN/A$1.80+2.3%N/AN/A$39.59MN/A-0.589Earnings ReportGap DownHigh Trading VolumeATHEAlterity Therapeutics1.9635 of 5 stars$4.39-8.5%$12.00+173.3%+114.3%$38.93MN/A0.0010RNXTRenovoRx2.6686 of 5 stars$1.06flat$7.00+560.4%-12.9%$38.75M$43,000.00-1.866Positive NewsEarnings ReportAnalyst ForecastAnalyst RevisionATRAAtara Biotherapeutics4.0821 of 5 stars$6.47-11.0%$17.75+174.3%-60.6%$38.57M$128.94M-0.25330Earnings ReportGap DownPRLDPrelude Therapeutics3.085 of 5 stars$0.88+13.0%$4.00+353.2%-76.2%$38.50M$7M-0.50120Positive NewsGap UpXLOXilio Therapeutics2.6506 of 5 stars$0.73+3.0%$4.00+447.2%-28.1%$37.85M$6.34M-0.4370High Trading VolumeSCYXSCYNEXIS1.2826 of 5 stars$0.97+2.8%N/A-69.5%$37.75M$3.75M-1.3160Positive NewsEarnings ReportACRVAcrivon Therapeutics3.1897 of 5 stars$1.20+3.4%$19.17+1,497.2%-85.4%$37.63MN/A-0.4458Analyst RevisionHigh Trading VolumeBRNSBarinthus Biotherapeutics2.2934 of 5 stars$0.93+7.3%$5.17+455.6%-62.9%$37.52M$14.97M-0.62107AKTXAkari TherapeuticsN/A$1.41+11.9%N/A-16.2%$37.50MN/A0.009Analyst ForecastGap Down Related Companies and Tools Related Companies RNTX Competitors ATHE Competitors RNXT Competitors ATRA Competitors PRLD Competitors XLO Competitors SCYX Competitors ACRV Competitors BRNS Competitors AKTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
